News | Latest Breaking News Stories & Headlines

GSK expects softer sales growth for 2026

In the first outlook presented by new CEO Luke Miels, GSK said today it expected slower sales growth in 2026 compared with a year earlier, as it expands its pipeline to counter looming patent expiries for its top-selling HIV drugs.

Business • 5 hrs

GSK chief executive Emma Walmsley to step down in January

British drugmaker GSK said today that Emma Walmsley will step down as CEO after nine years in the role and will be replaced by insider Luke Miels in January.

Business • 29 Sep 25

Emma Walmsley, the CEO of British drugmaker GSK

GSK beats Q4 earnings estimates, lifts 2031 sales target

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine.

Business • 05 Feb 25

Emma Walmsley, the CEO of UK drugmaker GSK

GSK warns of lower 2024 vaccine sales on weaker demand

GSK said today its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, sending its shares 4% lower in early trade.

Business • 30 Oct 24

GSK has today reported second-quarter core earnings per share (EPS) of 43.4 pence on sales of £7.88 billion

GSK lifts profit and sales forecasts after quarterly beat

British drugmaker GSK has today raised its annual earnings and sales forecasts after beating second-quarter expectations on strong sales of its cancer and HIV treatments, but its weak vaccines sales and outlook weighed on the shares.

Business • 31 Jul 24

GSK said today it expects 2024 sales to grow in the upper end of its 5% to 7% forecast range

GSK ups 2024 profit forecast, says sales growth to slow

GSK has today raised its full-year profit forecast on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half.

Business • 01 May 24

CEO Emma Walmsley said that GSK's longer-term outlook continues to strengthen

GSK lifts forecasts on strong launch of RSV vaccine

GSK has today raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine.

Business • 01 Nov 23

GSK said it now expects adjusted earnings per share growth of 14%-17% for the year, up from its earlier expectations of 12%-15%

GSK ups 2023 outlook boosted by vaccine, HIV drug sales

GSK has today raised its full-year profit and sales guidance after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.

Business • 26 Jul 23

GSK said that sales from its Covid-19 antibody treatment stood at £1.3 billion in the quarter

GSK tops quarterly results expectations

GSK has today beaten analyst expectations for its first-quarter results and stood by its forecasts for 2022 on the back of robust uptake of its drugs.

Business • 27 Apr 22

GSK's Covid-related sales hit £1.4 billion

GSK racked up £1.4 billion in Covid-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm.

Business • 09 Feb 22

GSK does not see mass-produced vaccine before mid-2021

GlaxoSmithKline, the world's largest vaccine maker, said the global push to develop an immunisation against the coronavirus would not lead to widely available products before the second half of next year.

Business • 29 Apr 20

GSK expects shingles drug sales to exceed $1.3 billion

GlaxoSmithKline has forecast 2019 sales of its fast-growing shingles vaccine Shingrix to be "significantly" more than £1 billion today as the drugmaker outpaced first quarter forecasts.

Business • 01 May 19

GSK CEO Emma Walmsley said today's deal will accelerate efforts to improve its performance

GSK buys Novartis stake in consumer healthcare venture

GlaxoSmithKline said today it will buy Novartis's 36.5% stake in their consumer healthcare joint venture for $13 billion in cash, and will also begin a strategic review of some other businesses.

Business • 27 Mar 18

Emma Walmsley